Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.FREQ · Entity 6388 | Chief Scientific Officer | July 27, 2023 | July 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date July 27, 2023 · Filed July 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,650 |
Ending reported balance
After 2023-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-27 · Sale · Disposed 1,373 · Balance 184,994 F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.502 to $0.543. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Row 2 · 2023-07-28 · Sale · Disposed 1,344 · Balance 183,650 F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.461 to $0.471. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.502 to $0.543. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.461 to $0.471. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2021 Filed Feb 3, 2021 22:58 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $45.02 | $360,196.00 |
DisclosureSEC source: 0001127602-21-003789 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $45 to $45.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 22:24 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $42.50 | $340,000.00 |
DisclosureSEC source: 0001127602-21-002856 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 22:57 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 70,000 | $0.00 Strike: $35.85 | $0.00 |
DisclosureSEC source: 0001127602-21-002022 · form4.xml · derivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 01:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,000 | $42.50 | $85,001.20 |
DisclosureSEC source: 0001127602-20-031890 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $42.5 to $42.52. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 01:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 6,000 | $40.00 | $240,000.00 |
DisclosureSEC source: 0001127602-20-031890 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| December 16, 2020 Filed Dec 16, 2020 22:15 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,000 | $40.00 | $160,000.00 |
DisclosureSEC source: 0001127602-20-031578 · form4.xml · nonDerivative · entry 4 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| December 16, 2020 Filed Dec 16, 2020 22:15 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,000 | $37.87 | $151,480.00 |
DisclosureSEC source: 0001127602-20-031578 · form4.xml · nonDerivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 22:15 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $37.28 | $298,240.00 |
DisclosureSEC source: 0001127602-20-031578 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $36.62 to $37.50. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:15 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $35.00 | $280,000.00 |
DisclosureSEC source: 0001127602-20-031578 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| November 09, 2020 Filed Nov 9, 2020 21:34 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $24.00 | $192,000.00 |
DisclosureSEC source: 0001127602-20-028483 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:34 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $23.00 | $184,000.00 |
DisclosureSEC source: 0001127602-20-028483 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 20:29 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $22.00 | $176,000.00 |
DisclosureSEC source: 0001127602-20-026930 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 21:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $21.12 | $168,960.00 |
DisclosureSEC source: 0001127602-20-026721 · form4.xml · nonDerivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $20.00 | $160,010.40 |
DisclosureSEC source: 0001127602-20-026721 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $20.00 to $20.10. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 21:54 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $19.46 | $155,680.00 |
DisclosureSEC source: 0001127602-20-026721 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 21:14 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $18.35 | $146,800.00 |
DisclosureSEC source: 0001127602-20-026567 · form4.xml · nonDerivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 21:14 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $18.92 | $151,360.00 |
DisclosureSEC source: 0001127602-20-026567 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:14 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,000 | $18.84 | $150,720.00 |
DisclosureSEC source: 0001127602-20-026567 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 12:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 24 | $22.43 | $538.32 |
DisclosureSEC source: 0001127602-20-025709 · form4.xml · nonDerivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 12:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,606 | $21.57 | $56,201.00 |
DisclosureSEC source: 0001127602-20-025709 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,806 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.25 to $22.19. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 12:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,870 | $20.51 | $38,357.63 |
DisclosureSEC source: 0001127602-20-025709 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,412 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $20.15 to $20.96. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 776 | $19.26 | $14,943.90 |
DisclosureSEC source: 0001127602-20-024908 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,282 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.16 to $19.39. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 3,724 | $18.91 | $70,424.94 |
DisclosureSEC source: 0001127602-20-024908 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,058 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.14 to $19.14. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 20:29 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,500 | $22.97 | $103,349.70 |
DisclosureSEC source: 0001127602-20-023991 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.77 to $23.24. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 21:15 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 58 | $21.91 | $1,270.70 |
DisclosureSEC source: 0001127602-20-023081 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,282 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.85 to $21.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 21:15 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,442 | $21.21 | $94,193.05 |
DisclosureSEC source: 0001127602-20-023081 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,340 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $20.72 to $21.66. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 21:10 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,500 | $21.51 | $96,790.50 |
DisclosureSEC source: 0001127602-20-022045 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.31 to $21.70. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:30 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 779 | $22.97 | $17,891.29 |
DisclosureSEC source: 0000899243-20-018925 · doc4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,282 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.92 to $23.02. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:30 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 3,721 | $22.18 | $82,547.78 |
DisclosureSEC source: 0000899243-20-018925 · doc4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,061 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.87 to $22.80. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 22:18 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,500 | $22.80 | $102,586.95 |
DisclosureSEC source: 0001127602-20-020363 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.33 to $23.12. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,500 | $19.96 | $89,829.00 |
DisclosureSEC source: 0001127602-20-019507 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,282 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.72 to $20.26. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 20, 2020 Filed May 22, 2020 21:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,832 | $19.33 | $35,408.35 |
DisclosureSEC source: 0001127602-20-017821 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,282 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.23 to $19.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 20, 2020 Filed May 22, 2020 21:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,668 | $18.82 | $50,202.16 |
DisclosureSEC source: 0001127602-20-017821 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,114 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.23 to $19.22. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 06, 2020 Filed May 7, 2020 21:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 554 | $16.68 | $9,240.22 |
DisclosureSEC source: 0001127602-20-015786 · form4.xml · nonDerivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.61 to $16.79. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 06, 2020 Filed May 7, 2020 21:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 3,946 | $16.23 | $64,028.19 |
DisclosureSEC source: 0001127602-20-015786 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $15.59 to $16.58. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 30, 2020 Filed Jan 28, 2021 22:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002847 · form5.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,782 Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:52 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,500 | $14.84 | $66,794.40 |
DisclosureSEC source: 0001127602-20-014478 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,282 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $14.51 to $15.1. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 19:17 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,500 | $14.99 | $67,468.50 |
DisclosureSEC source: 0001127602-20-013565 · form4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $14.71 to $15.68. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:23 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 57,500 | $0.00 Strike: $25.05 | $0.00 |
DisclosureSEC source: 0001127602-20-005641 · form4.xml · derivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 20:00 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 64,241 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-028543 · doc4.xml · derivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,241 Underlying: Common Stock · 64,241 shares Expires 2029-04-16 F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 00:30 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionSeries A Preferred Stock · Derivative | 45,182 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025214 · doc4.xml · derivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 00:30 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionCommon Stock | 6,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025214 · doc4.xml · nonDerivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 01:42 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 146,826 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024835 · doc4.xml · derivative · entry 3 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,826 Underlying: Common Stock · 146,826 shares Expires 2029-10-01 F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| April 17, 2019 Filed Oct 3, 2019 01:42 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 360,606 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-024835 · doc4.xml · derivative · entry 2 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,606 Underlying: Common Stock · 360,606 shares Expires 2029-04-16 F1 · security: This transaction is being reported pursuant to Rule 16a-2(a), and the securities covered by such transaction were previously included on the Reporting Person's Form 3. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2019, and will be fully vested and exercisable on January 1, 2023. Read SEC document |
| April 17, 2019 Filed Oct 3, 2019 01:42 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 64,241 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-024835 · doc4.xml · derivative · entry 1 Loose Christopher R. · CIK 0001785299 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,241 Underlying: Common Stock · 64,241 shares Expires 2029-04-16 F1 · security: This transaction is being reported pursuant to Rule 16a-2(a), and the securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.